GI-102 plus GIB-7 to target immune aging and gut‑brain‑muscle health

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2a interventional study gives participants either the GI-102 plus GIB-7 combination or placebo and measures a range of biological markers linked to aging. GI-102 is a bispecific immunocytokine designed to reactivate immune cells and lower inflammation, while GIB-7 is a synbiotic intended to support the gut‑brain‑muscle axis and circadian regulation. The study enrolls adults and cancer survivors who meet specific remission and treatment criteria and follows biomarker, immune cell, metabolic, and functional endpoints. Safety, tolerability, and changes in peripheral lymphocyte counts and inflammatory/metabolic markers are key outcomes.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Must be aged between ≥18 and ≤80 years old at the time of informed consent.
2. At the discretion of the Investigator, must be in a state of general health that is not severely compromised (ie, no life-threatening illness or disability).
3. Participants with a history of cancer may be included only if they meet one of the following:

   1. Participants have been disease-free for ≥2 years; OR
   2. For those diagnosed within 2 years:

      * The cancer was treated with curative intent (eg, surgery, anti-cancer agents including chemotherapy)
      * Participants have been in remission for ≥12 months
      * Participants are not on any active cancer treatment except maintenance therapies (eg, endocrine therapy or bisphosphonates)
      * Participants must have received systemic anti-cancer therapies without immunotherapy for their cancers
4. Women of childbearing potential (WOCBP; see definition in Section 5.3) must agree to use a highly effective method of contraception from 14 days prior to Visit 2 until 180 days after the last dose of study medication (GI-102 or GIB-7). Fertile men must agree to use an acceptable method of contraception from 14 days prior to Visit 2 until 90 days after the last dose of study medication (GI-102 or GIB-7).

Key Exclusion Criteria:

1. Severe and poorly managed chronic diseases, such as advanced cardiovascular disease, kidney failure requiring transplant or dialysis, uncontrolled diabetes, detectable malignancy (≤ 2 years), severe chronic obstructive pulmonary disease (COPD), or untreatable, terminal cancer as judged by the Investigator or history of life threatening infection (eg, meningitis).
2. Dependent on walkers or wheelchairs; severe difficulty or inability to perform activities of daily living independently or inability to perform study measures required to test muscle function (an amputee is eligible if participants can walk without walkers or wheelchair) as judged by the Investigator.
3. Major surgery within the past 6 months or scheduled during the study period, including severe orthopedic diseases requiring joint replacement surgery.
4. History of substance abuse or dependency or history of recreational IV drug use over the last 5 years (by self-declaration).
5. Female participants who are pregnant, planning to become pregnant, or breastfeeding during the study period. Participants undergoing perimenopause or the menopause transition are eligible.

Where it's running

• Novatrials
  Charlestown, New South Wales, Australia Recruiting
• Southern Oncology Clinical Research Unit
  Adelaide, South Australia, Australia Recruiting

Study contacts

• Study coordinator: Wayne Lee, Ph.D., MBA
• Email: woohyung.wayne.lee@gi-innovation.com
• Phone: +82-2-404-2003

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brief Behavioral Activation for cancer survivors 65+

  This study tests whether a short behavioral-activation therapy delivered by phone or video can help reduce depression and anxiety and improve well-being in English- or Spanish-speaking cancer survivors aged 65 and older.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768449

• How different particle sizes of Prifetrastat affect how much medicine gets into the blood

  This study tests whether prifetrastat tablets with different active ingredient particle sizes result in different amounts of medicine entering the bloodstream in healthy adults.

  Recruiting Phase 1 Pfizer · Brussels, Bruxelles-capitale, Région de · NCT07721402

• Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines

  This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.

  Recruiting at 2 sites St. James's Hospital, Ireland · Dublin and 1 other locations · NCT07561957

• Relaxation and stress-reduction using yoga or mindfulness for cancer survivors

  This study will test whether oncology-informed yoga or SMART mindfulness training can improve well-being and change epigenetic markers in adult survivors of lung, colon, and non-Hodgkin's lymphoma cancers.

  Recruiting Stony Brook University · Stony Brook, New York · NCT07161713

• Italian employers' perspectives on supporting employees who return to work after cancer

  This project will talk with Italian employers to see how they manage and support employees returning to work after a cancer diagnosis.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia, RE · NCT06994182

• Social needs screening and connection program for Metro Detroit cancer survivors

  This project will test whether cancer survivors in Metro Detroit can complete a social needs screening and be connected to community resources for food and digital access.

  Recruiting Barbara Ann Karmanos Cancer Institute · Detroit, Michigan · NCT06908629

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.